No Data
No Data
BrightGene Bio-Medical Technology Completes Phase II Clinical Trial for Weight Loss Drug
brightgene bio-medical technology co.,ltd. (688166.SH): BGM0504 injection achieved the expected goal in phase II clinical trial for overweight or obese non-diabetic patients.
Brightgene Bio-medical Technology Co., Ltd. (688166.SH) announced on October 13 that its wholly-owned subsidiary, Brightgene New Creation Biomedical Technology (Wuxi) Co., Ltd. (referred to as "Brightgene New Creation"), has achieved the expected target in the phase II clinical trial of BGM0504 injection developed independently for the treatment of non-diabetic overweight or obese individuals. The preliminary results of the phase II clinical trial for BGM0504 injection in the treatment of overweight or obese individuals show that the subjects in the 5mg, 10mg, and 15mg dose groups receiving once-weekly dosing for 26 to 30 weeks demonstrated good overall tolerability and safety.
Optimistic Investors Push BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Shares Up 28% But Growth Is Lacking
Is There An Opportunity With BrightGene Bio-Medical Technology Co., Ltd.'s (SHSE:688166) 46% Undervaluation?
Brightgene Bio-Medical Technology Co.,Ltd. (688166.SH): Its subsidiary Aiteme plans to carry out capital increase and share expansion.
GeLongHui, September 18th | brightgene bio-medical technology co.,ltd. (688166.SH) announced that, to support the development of the company's drug and device combination platform, meet the research and development and industrialization funding needs of products such as Etermei inhalation preparations, the controlling subsidiary Etermei plans to increase its capital. The total amount of this capital increase is 103 million yuan, of which Suzhou Hongbo Second Phase Investment Partnership Enterprise (Limited Partnership) (referred to as "Hongbo Second Phase") plans to subscribe to the newly increased registered capital of Etermei in the amount of 0.721397 million yuan in RMB for a price of 50 million yuan. Suzhou Dongwu Industrial M&A Guidance Fund Partnership Enterprise (Limited Partnership) (referred to as "Dongwu Fund").
BrightGene Bio-Medical Technology (SHSE:688166) Takes On Some Risk With Its Use Of Debt
No Data
No Data